Krishna M. Ella

Genome Valley, 500 078
Hyderabad, TG, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis.

Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis.

Journal: The Journal of infectious diseases

Published: January 08, 2026

A phase 1 randomized, placebo-controlled trial of a combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine.

A phase 1 randomized, placebo-controlled trial of a combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine.

Journal: medRxiv : the preprint server for health sciences

Published: September 26, 2025

A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.

A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.

Journal: Nature medicine

Published: March 03, 2025

Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.

Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.

Journal: Scientific reports

Published: March 19, 2022

Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.

Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.

Journal: The Lancet. Infectious diseases

Published: January 20, 2022

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: June 24, 2021

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.

Journal: The Lancet. Infectious diseases

Published: December 21, 2020

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.

Journal: The Lancet. Infectious diseases

Published: November 21, 2020

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.

Journal: iScience

Published: November 11, 2020

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.

Journal: iScience

Published: September 16, 2020

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques.

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques.

Journal: Nature communications

Published: August 28, 2020

Coronavirus Vaccine: Light at the End of the Tunnel.

Coronavirus Vaccine: Light at the End of the Tunnel.

Journal: Indian pediatrics

Published: April 16, 2020

Showing 1-12 of 22

Last Updated: 09/26/2026